Effects of opioid rotation to buprenorphine/naloxone on pain, pain thresholds, pain tolerance, and quality of life in patients with chronic pain and opioid use disorder. Issue 5 (23rd May 2022)

• Record Type: Journal Article
• Authors: Veldman, Stijn; van Beek, Maria; van Rijswijk, Steffie; Ellerbroek, Hannah; Timmerman, Hans; van der Wal, Selina; Steegers, Monique; Schellekens, Arnt
• Is Part Of: Pain. Volume 163:Issue 5(2022)
• Page Start: 955
• Page End: 963
• Publication Date: 2022-05-23
• Subjects: Buprenorphine/naloxone -- Suboxone -- Chronic pain -- Opioid induced hyperalgesia -- Pain threshold -- Pain tolerance -- Quality of life -- Opioid use disorder, Pain; Pain -- Periodicals; Douleur -- Périodiques; Anesthésie -- Périodiques; Pain; Electronic journals; Periodicals; Electronic journals; 616.0472
• DOI: 10.1097/j.pain.0000000000002462
• Languages: English
• ISSNs: 0304-3959

Abstract

Abstract : Inpatient conversion to buprenorphine or naloxone seems to have a beneficial effect on pain, pain thresholds, pain tolerance, and quality of life in patients with chronic pain and opioid use disorder. Abstract: Long-term opioid use in patients with chronic noncancer pain (CNCP) can lead to opioid use disorder (OUD) and has been associated with hyperalgesia and reduced quality of life (QoL). Studies suggest antihyperalgesic properties of buprenorphine, and buprenorphine or naloxone (BuNa) has shown beneficial effects on QoL in patients with OUD without CNCP. This study investigated the added value of BuNa in patients with CNCP with OUD on self-reported pain, pain thresholds, pain tolerance, and QoL. In the current study, 43 outpatients with CNCP and OUD were included for inpatient conversion from full μ-receptor agonist opioids to BuNa. Self-reported pain, pain thresholds, pain tolerance, and QoL were determined at baseline and after 2 months of follow-up, using, respectively, a Visual Analogue Scale (VAS-pain and VAS-QoL), quantitative sensory testing, and EuroQol-5 dimensions. In total, 37 participants completed the protocol, and their data were analyzed. The mean VAS-pain score decreased from 51.3 to 37.2 (27.5%, F = 3.3; P = 0.044), whereas the pressure pain threshold and electric pain threshold or tolerance increased after substitution (F = 7.8; P = 0.005 and F = 44.5; P < 0.001, respectively), as well as QoL (EuroQol-5 dimensions questionnaire: F = 10.4; P = 0.003 and VAS-QoL: F = 4.4; P = 0.043). We found that conversion of full μ-receptor agonists to BuNa, in patients with CNCP with OUD, was accompanied with lower self-reported pain, higher pain thresholds, higher pain tolerance, and improved QoL. Despite several study limitations, these data suggest that BuNa might be of value in patients with CNCP with OUD. Future studies should investigate long-term effects of BuNa in randomized trials.